# overview
is an Assistant Professor of Rangel College of Pharmacy. Her research interest lies at the intersection of science, medicine and economics to assess clinical, economic and humanistic values of medical interventions and she conducts research on the costs and outcomes associated with pharmaceutical products.

She has conducted research using clinical trial data, real world data, large survey data and economic modeling to study cost-effectiveness of new interventions for cancer and neurological diseases. Since joining Texas A&M University as an assistant professor at the College of Pharmacy in 2015, she is conducting research in: evaluating utilization, costs and outcomes associated with medications and other health care services in patients with chronic diseases, health disparity, cost-effectiveness of new interventions, drug pricing and reimbursement.

She holds a Ph.D in Pharmacology and an M.A. in Economics from Duke University. She completed her post-doctoral fellowship training in Pharmacoeconomics and Outcomes research from University of California, San Francisco. She has conducted research in academic, international organization and industry settings.

# keywords[]
6 Evaluation Of Treatments And Therapeutic Interventions

# keywords[]
6 Evaluation Of Treatments And Therapeutic Interventions

# keywords[]
Clinical Trials And Supportive Activities

# educationAndTraining[].organization.label
Duke University - (Durham, North Carolina, United States)

# educationAndTraining[].organization.label
Peking University - (Beijing, Beijing, China)

# educationAndTraining[].organization.label
Duke University - (Durham, North Carolina, United States)

# publications[].label
Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?

# publications[].label
Meeting Abstracts - AMCP 2020  - Effect of an Asthma-Related Educational Intervention Targeting Pharmacies in a Managed Care Organization CHIP/Medicaid Network in the Provision of Pharmaceutical Care Incentive Programs for Asthma and Patients' Process and Outcomes Measures

# publications[].label
EPIDEMIOLOGY AND ECONOMIC BURDEN OF SYSTEMIC SCLEROSIS - A SYSTEMATIC REVIEW

# publications[].label
Egg Laying Decisions in Drosophila Are Consistent with Foraging Costs of Larval Progeny

# publications[].label
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?

# publications[].label
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.

# publications[].label
Disease Burden of Prostate Cancer from 2014 to 2019: Estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey.

# publications[].label
HEALTH EQUITY CONSIDERATIONS IN MINORITY GROUPS WITH TYPE 1 AND 2 DIABETES IN THE COVID-19 ERA: CARE UTILIZATIONS AND COSTS

# publications[].label
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA.

# publications[].label
IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS

# publications[].label
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.

# publications[].label
Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.

# publications[].publisher
Computers, Materials and Continua (Tech Science Press)

# publications[].label
Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.

# publications[].label
NEONATAL ABSTINENCE SYNDROME INCIDENCE RATE, CLINICAL CHARACTERISTICS & HEALTHCARE RESOURCE UTILIZATION IN TEXAS DURING 2006-2017

# publications[].label
BUDGET IMPACT ANALYSIS OF NIRAPARIB AND OLAPARUB AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE, RECURRENT OVARIAN CANCER IN THE US

# publications[].label
Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence.

# publications[].label
UTILIZATION PATTERN OF PRESCRIPTION PAIN MEDICATION AMONG ADULTS WITH DIABETES MELLITUS

# publications[].label
Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis.

# publications[].label
Real-World Data on Liposomal Bupivacaine and Inpatient Hospital Costs After Colorectal Surgery.

# publications[].label
PND3 The Population-Based Impact of MS in Asia

# publications[].label
Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.

# publications[].label
Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.

# publications[].publisher
American Society of Clinical Oncology (ASCO)

# publications[].label
HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis

# publications[].label
CO31 Health Equity Considerations in Minority Groups with Type 1 and 2 Diabetes in the COVID-19 Era: Care Utilizations and Costs

# publications[].label
Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis.

# publications[].label
COST-EFFECTIVENESS OF RIBOCICLIB PLUS ENDOCRINE THERAPY IN TREATING PREMENOPAUSAL OR PERIMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN THE UNITED STATES

# publications[].label
Patient centered decision making: Use of conjoint analysis to determine riskbenefit trade-offs for preference sensitive treatment choices

# publications[].label
Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey.

# publications[].label
A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.

# publications[].label
Nociceptive Neurons Protect Drosophila Larvae from Parasitoid Wasps

# publications[].label
COST-EFFECTIVENESS OF NIRAPARIB AND OLAPARIB AS MAINTENANCE THERAPY FOR PATIENTS WITH PLATINUM SENSITIVE < RECURRENT OVARIAN CANCER

# publications[].label
PCN72 Cost Effectiveness Analysis of New Treatments for Metastatic Castration-Resistant Prostate Cancer: Does Severity Matter?

# publications[].label
EVALUATION OF TUCATINIB FOR HER2-POSITIVE BREAST CANCER PATIENTS WITH BRAIN METASTASES: A UNITED STATES-BASED COST-EFFECTIVENESS ANALYSIS

# publications[].label
EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis

# publications[].label
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.

# publications[].label
IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS

# publications[].label
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women.

# publications[].label
Pickpocket Is a DEG/ENaC Protein Required for Mechanical Nociception in Drosophila Larvae

# publications[].label
LIPOSOMAL BUPIVACAINE AND INPATIENT HOSPITAL COSTS AFTER COLORECTAL SURGERY

# publications[].label
Physicians' interest in different strategies for supporting pain -management and opioid prescribing: A cross-sectional study.

# publications[].label
PND37 Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis

# publications[].label
Impact of a pharmaceutical care incentive program on the asthma medication ratio among pediatric patients with persistent asthma enrolled in a Medicaid program.

# publications[].label
Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies

# publications[].publisher
Consortium of Multiple Sclerosis Centers

# publications[].label
Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems.

# publications[].label
PSU5 Liposomal Bupivacaine and Inpatient Hospital Costs after Colorectal Surgery

# publications[].label
The economic burden of systemic sclerosis-A systematic review.

# publications[].label
Thermosensory and Nonthermosensory Isoforms of Drosophila melanogaster TRPA1 Reveal Heat-Sensor Domains of a ThermoTRP Channel